Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 24.7688
- Book/Share 29.2044
- PB 4.4244
- Debt/Equity 0.2657
- CurrentRatio 1.8207
- ROIC 0.188
- MktCap 223718601660.0
- FreeCF/Share 3.8927
- PFCF 33.0212
- PE 16.0039
- Debt/Assets 0.16
- DivYield 0.0184
- ROE 0.2993
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABT | The Benchmark Company | -- | Buy | -- | $145 | Oct. 10, 2025 |
| Upgrade | ABT | Jefferies | Hold | Buy | -- | $145 | July 18, 2025 |
| Initiation | ABT | Leerink Partners | -- | Market Perform | -- | $143 | June 16, 2025 |
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
Read More
Abbott Laboratories' October Price Plunge Is a Signal to Buy
Published: October 17, 2025 by: MarketBeat
Sentiment: Negative
Abbott Laboratories' NYSE: ABT October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat data include increasing coverage with newly initiated ratings appearing within days of the Q3 earnings release.
Read More
Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Positive
The Goldman Sachs Conviction List is a curated list of stocks that the firm's research team believes have a high likelihood of outperforming the market.
Read More
Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Negative
Abbott Laboratories delivered solid Q3 2025 results, with diversified growth across medical devices, nutrition, and branded generics offsetting diagnostics weakness. ABT's international presence and exposure to emerging markets drive structural growth, while its broad portfolio provides resilience amid global economic volatility. Tariffs and China remain key risks, but ABT's flexible supply chain and reduced China exposure help limit downside, with management actively shifting focus to other regions.
Read More
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
Published: October 15, 2025 by: Benzinga
Sentiment: Neutral
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.
Read More
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Abbott Laboratories (NYSE:ABT ) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Joshua Jennings - TD Cowen, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Joanne Wuensch - …
Read More
NVST or ABT: Which Is the Better Value Stock Right Now?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
Read More
Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Abbott Laboratories posts steady sales growth in Q3, reaffirms full-year guidance
Published: October 15, 2025 by: Proactive Investors
Sentiment: Positive
Abbott Laboratories (NYSE:ABT) reported steady growth in the third quarter, with sales rising 6.9% to $11.37 billion, slightly below estimates of $11.4 billion, and adjusted earnings per share matching expectations at $1.30. The company's results were driven by broad-based strength across Abbott's medical devices and diagnostics businesses, even as COVID-19 testing-related revenue continued to normalize.
Read More
Abbott (ABT) Q3 Earnings Meet Estimates
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) came out with quarterly earnings of $1.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.21 per share a year ago.
Read More
Worried Investors Should Look at the 5 Safest Dividend Kings Right Now
Published: October 13, 2025 by: 24/7 Wall Street
Sentiment: Neutral
First, it was David Solomon from Goldman Sachs, then Jamie Dimon from J.P.
Read More
Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.
Read More
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
Published: September 30, 2025 by: Proactive Investors
Sentiment: Positive
UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard. In a note to clients on Tuesday, the analysts wrote that healthcare equipment has had the highest growth rate historically, excluding technology, at a 9% compound annual growth rate (CAGR) and the sector's earnings per share are now trading 10% below trend.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
Read More
Abbott Hosts Conference Call for Third-Quarter Earnings
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.
Read More
1 Dividend King To Hold And 2 Worth Buying Now
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
It's often said that cash is king, but I would take it one step further. Abbott Laboratories is an AA-rated Dividend King with healthy growth prospects but a rich valuation. I'm waiting for a pullback to the low-$120 range before upgrading back to a buy. Federal Realty owns top-notch properties in demographically thriving markets, possesses a conservatively leveraged balance sheet, and has the longest track record of dividend growth in REITdom.
Read More
Abbott Declares 407th Consecutive Quarterly Dividend
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
Read More
Is it the Right Time to Retain Abbott Stock in Your Portfolio?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.
Read More
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.
Read More
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, according to Grand View Research. Abbott Laboratories ABT and Edwards Lifesciences EW are two key players with significant presence in this sector.
Read More
Best Dividend Aristocrats For September 2025
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.
Read More
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Robert B. Ford
- Employees 114000